Accelerate Diagnostics Inc (NASDAQ:AXDX) was the target of some unusual options trading on Monday. Investors purchased 3,074 call options on the stock. This represents an increase of approximately 713% compared to the typical volume of 378 call options.

In related news, Director Jack W. Schuler acquired 5,500 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was acquired at an average price of $22.00 per share, for a total transaction of $121,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 50.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of AXDX. Artal Group S.A. lifted its stake in Accelerate Diagnostics by 150.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the medical research company’s stock worth $13,100,000 after purchasing an additional 300,000 shares during the last quarter. Deutsche Bank AG lifted its stake in Accelerate Diagnostics by 1,236.9% during the fourth quarter. Deutsche Bank AG now owns 312,470 shares of the medical research company’s stock worth $8,185,000 after purchasing an additional 289,098 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Accelerate Diagnostics during the fourth quarter worth approximately $5,311,000. Next Century Growth Investors LLC lifted its stake in Accelerate Diagnostics by 30.5% during the fourth quarter. Next Century Growth Investors LLC now owns 660,020 shares of the medical research company’s stock worth $17,292,000 after purchasing an additional 154,387 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its stake in Accelerate Diagnostics by 37.3% during the third quarter. Kornitzer Capital Management Inc. KS now owns 530,219 shares of the medical research company’s stock worth $11,903,000 after purchasing an additional 144,055 shares during the last quarter. Hedge funds and other institutional investors own 47.56% of the company’s stock.

Several brokerages have recently issued reports on AXDX. BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. Finally, BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $33.00.

Accelerate Diagnostics (NASDAQ:AXDX) traded up $0.35 during mid-day trading on Wednesday, reaching $23.25. The company had a trading volume of 415,977 shares, compared to its average volume of 283,132. The stock has a market capitalization of $1,290.00, a PE ratio of -19.38 and a beta of 2.19. Accelerate Diagnostics has a 12-month low of $16.75 and a 12-month high of $30.45.

WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/02/14/stock-traders-purchase-high-volume-of-call-options-on-accelerate-diagnostics-axdx.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.